Grace Halsey

GLORY-2 participants showed continuous weight loss through 60 weeks with no plateau; mazdutide also improved multiple cardiometabolic markers.

Life-course analysis sheds light on how movement patterns influence brain resilience, giving clinicians new context for counseling about dementia prevention.

Eisai and Acumen Therapeutics will present new data in areas including long-term outcomes, brain delivery strategies, and early-stage Alzheimer disease.

Deep TMS becomes first FDA-cleared brain stimulation therapy for adolescents with treatment-resistant depression and is now available for ages 15-86 for MDD treatment.

TMS: Harvard's Caroline Mitchell, MD, MPH, questions the direction of genitourinary syndrome research priorities and reflects on FDA's removal of HRT warnings.

UK neurodivergent adults report strong views on neurodiversity terminology, emphasizing correct usage and its role in stigma, identity, and communication.

In the phase 2 clinical trial, tradipitant, an oral neurokinin-1 receptor antagonist, was dosed twice daily among adults with obesity and treated with semaglutide.

Individuals who have chronic widespread pain showed a 75% increased risk of developing hypertension compared to fellow UK Biobank participants who were pain-free.

Higher surprisal scores, measuring how atypical a daily experience is, increased migraine odds by 86% at 12 hours and 115% at 24 hours in new cohort study.

LEO Pharma reveals promising 32-week results for tralokinumab, showing significant benefits for adults with moderate-to-severe hand eczema.

Harvard's Caroline Mitchell, MD, MPH, explains how common OTC products can worsen vulvovaginal symptoms and the importance of a targeted history in GSM care.

Nearly 40% of perimenopausal women report misdiagnosis as clinicians treat for anxiety and depression without addressing underlying hormonal imbalance.

The comprehensive timeline highlights how WHI findings and subsequent research reshaped HRT risk assessment, guidance, and FDA labeling through 2025.

A geriatric psychiatrist's clinical pearls on agitation in AD, incluiding behavioral cues, triggers, and evidence-based treatment strategies for primary care.

A 10-year microsimlation model of annual MCED testing revealed signficant reductions in late-stage cancer diagnoses, particularly for cancers lacking routine screening,

Many caregivers, both paid and unpaid, miss or misinterpret agitation symptoms in Alzheimer disease, fueling stress, stigma, and delayed medical support.

Mitchell highlights hormone therapy prescribing for primary care: treatment algorithms, vaginal estrogen safety, and when progestins aren't needed.

Research reveals metformin's potential to enhance sinus rhythm stability post-ablation for AF in adults with obesity, independent of weight loss.

Indiana University study found that integrating patient-reported outcome questionnaires with machine learning boosts dementia diagnoses by 31% in primary care settings.

The TARGET-D trial found targeted vitamin D dosing post-MI didn’t lower MACE but reduced recurrent MI risk, supporting individualized serum-level management.

Recognize Cushing syndrome in primary care: key clinical clusters, first-line screening tests (DST, salivary cortisol, UFC), and when to refer to endocrinology.

Sublingual epinephrine film matches adult PK/PD in kids aged 7-17 with a history of allergic reactions and high risk for serious allergic reactions, incluing anaphylaxis.

Merck's oral PCSK9 inhibitor enlicitide demonstrated antibody-like LDL-C lowering in adutls with HeFH with safety profile similar to placebo in phase 3 trial.

Phase 2b findings show rezpegaldesleukin reduced ACQ-5 scores and improved key AD endpoints in participants with comorbid asthma.

Submission of the sNDA suggests a potential FDA decision on the dextromethorphan-bupropion combination sometime during the first quarter of 2026.

Nearly 40% of REDEFINE 1 participants taking antihypertensive medications reduced or discontinued their blood pressure drugs during the trial, Novo Nordisk reported.

Adults with diabetes often face obstacles to optimal disease management in the workplace. Use this checklist in the clinic to help them navigate the barriers.

TMS 2025: Dr Marla Shapiro doesn't start perimenopausal therapy without an answer to the most important question: "What is your most bothersome symptom?"

Trump announces deals with Eli Lilly and Novo Nordisk slashing GLP-1 prices to as low as $150/month, expanding Medicare coverage starting mid-2026.

Oral semaglutide 25 mg improved glucose control and CV risk factors across weight loss categories in OASIS 4 post hoc analysis presented at ObesityWeek 2025.